A branch of Kangzhiyuan in Shenzhen was fined for failing to display and store medicines as required

China Economic Net, Beijing, August 2nd. Recently, the administrative penalty decision (Shenzhen Jianbao Punishment [2022] Shiyan No. 80) published on the website of Shenzhen Market Supervision Administration showed that Shenzhen Kangzhiyuan Pharmaceutical Co., Ltd. (referred to as “Kangzhiyuan” on the New Fourth Board, 661546) The Guantian branch did not display and store drugs in accordance with the relevant regulations on drug classification management, and there were drug violations.

According to Article 41 of the Measures for the Supervision and Administration of Drug Retailing in Shenzhen, “Anyone who violates the provisions of Article 18 of these Measures and fails to display and store drugs in accordance with the regulations on drug classification management shall be ordered by the drug supervision department to make corrections within a time limit, and shall be punished by one A fine of 1,000 yuan”, and the Shenzhen Market Supervision and Administration Bureau Bao’an Supervision Bureau fined the branch 1,000 yuan.

According to a reporter from China Economic Net, the major shareholder of Shenzhen Kangzhiyuan Pharmaceutical Co., Ltd. is Dongfuhai Pharmaceutical (Shenzhen) Group Co., Ltd., holding 80.00% of the shares.

According to the official website of Kangzhiyuan, Shenzhen Kangzhiyuan Pharmaceutical Co., Ltd. was established in 2003 with a registered capital of 15 million yuan. Its subordinate units include Shenzhen Guolitang Pharmaceutical Co., Ltd., Guangdong Jiazhihe Pharmaceutical Co., Ltd., and Guangdong Jiazhihe Pharmaceutical (Chain) Co., Ltd., Shenzhen Huijia Wine Co., Ltd., Huizhou Jiazhihe Pharmaceutical Co., Ltd.

The following is the original text: